RedShift BioAnalytics
Provides a next-generation infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery.
Launch date
Employees
Market cap
-
Enterprise valuation
$80—120m (Dealroom.co estimates Oct 2021.)
Burlington Vermont (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$12.0m | Series A | ||
$3.0m | Series B | ||
| N/A | $750k | Seed | |
| N/A | $1.0m | Seed | |
$11.0m | Series C | ||
$18.0m | Series D | ||
$20.0m | Series E | ||
| Total Funding | $65.8m | ||
Related Content
Recent News about RedShift BioAnalytics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.